Cargando…

EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy

BACKGROUND: Toll-like receptor 9 agonists are potent activators of the immune system. Their clinical potential in immunotherapy against metastatic cancers is being evaluated across a number of clinical trials. TLR9 agonists are DNA-based molecules that contain several non-methylated CG-motifs for TL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kapp, Kerstin, Volz, Barbara, Curran, Michael A., Oswald, Detlef, Wittig, Burghardt, Schmidt, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323716/ https://www.ncbi.nlm.nih.gov/pubmed/30621769 http://dx.doi.org/10.1186/s40425-018-0470-3

Ejemplares similares

Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors
por: Kapp, Kerstin, et al.
Publicado: (2019)

Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist
por: Volz, Barbara, et al.
Publicado: (2016)

Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703
por: Schmidt, Manuel, et al.
Publicado: (2015)

Mode of action of maintenance immunotherapy therapy with the TLR-9 agonist MGN1703 in metastatic colorectal carcinoma: the Phase III IMPALA study
por: Stein, Alexander, et al.
Publicado: (2015)

Genuine Immunomodulation With dSLIM
por: Kapp, Kerstin, et al.
Publicado: (2014)

Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity
por: Younes, Ahmed I., et al.
Publicado: (2020)

The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma
por: Zhou, Zhimei, et al.
Publicado: (2021)

TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes
por: Schleimann, Mariane H., et al.
Publicado: (2019)

The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon
por: Krarup, Astrid Raaby, et al.
Publicado: (2017)

Immunotherapy of Malignant Glioma by Noninvasive Administration of TLR9 Agonist CpG Nano‐Immunoadjuvant
por: Wei, Jingjing, et al.
Publicado: (2022)

Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial
por: Schmoll, Hans-Joachim, et al.
Publicado: (2014)

Route of Administration of the TLR9 Agonist CpG Critically Determines the Efficacy of Cancer Immunotherapy in Mice
por: Nierkens, Stefan, et al.
Publicado: (2009)

Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2020)

Comparison of human B cell activation by TLR7 and TLR9 agonists
por: Hanten, John A, et al.
Publicado: (2008)

Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
por: Smirnov, DV, et al.
Publicado: (2013)

Correction to: Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2021)

Human CD14(dim) Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 Receptors
por: Cros, Jérôme, et al.
Publicado: (2010)

Intraperitoneal injection of class A TLR9 agonist enhances anti–PD-1 immunotherapy in colorectal peritoneal metastases
por: Jiang, Ting, et al.
Publicado: (2022)

Immunotherapy with STING and TLR9 agonists promotes synergistic therapeutic efficacy with suppressed cancer-associated fibroblasts in colon carcinoma
por: Hajiabadi, Sare, et al.
Publicado: (2023)

TLR9 agonists induced cell death in Burkitt's lymphoma cells is variable and influenced by TLR9 polymorphism
por: Noack, J, et al.
Publicado: (2012)

Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients
por: Kuznetsov, Nikolai V, et al.
Publicado: (2014)

Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
por: Bhatnagar, Shubhmita, et al.
Publicado: (2022)

TLR3 and TLR9 Agonists Improve Postexposure Vaccination Efficacy of Live Smallpox Vaccines
por: Israely, Tomer, et al.
Publicado: (2014)

Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells
por: Shen, Kuan-Yin, et al.
Publicado: (2020)

Distinct immunological activation profiles of dSLIM® and ProMune® depend on their different structural context
por: Kapp, Kerstin, et al.
Publicado: (2016)

Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma
por: Cascini, Caterina, et al.
Publicado: (2023)

Overexpression of TLR2 and TLR9 on monocyte subsets of active rheumatoid arthritis patients contributes to enhance responsiveness to TLR agonists
por: Lacerte, Patricia, et al.
Publicado: (2016)

TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects
por: Lu, Hailing
Publicado: (2014)

Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma
por: Deng, Shuanglin, et al.
Publicado: (2014)

Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy
por: Rodell, Christopher B., et al.
Publicado: (2019)

The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview
por: Veneziani, Irene, et al.
Publicado: (2022)

CD56(dim)CD16(dim) Natural Killer (NK) Cells: The Forgotten Population
por: Zimmer, Jacques
Publicado: (2020)

TLR9 Agonist Protects Mice from Radiation-Induced Gastrointestinal Syndrome
por: Saha, Subhrajit, et al.
Publicado: (2012)

Human CD56(dim)CD16(dim) Cells As an Individualized Natural Killer Cell Subset
por: Amand, Mathieu, et al.
Publicado: (2017)

Differential Adjuvant Activities of TLR7 and TLR9 Agonists Inversely Correlate with Nitric Oxide and PGE(2) Production
por: Lee, Jinhee, et al.
Publicado: (2015)

Dimming Titan Revealed by the Cassini Observations
por: Li, Liming
Publicado: (2015)

Dim Light Exposure and Myopia in Children
por: Landis, Erica G., et al.
Publicado: (2018)

The Plant Derived 3-3′-Diindolylmethane (DIM) Behaves as CB(2) Receptor Agonist in Prostate Cancer Cellular Models
por: Tucci, Paolo, et al.
Publicado: (2023)

An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy
por: Zhang, Huagang, et al.
Publicado: (2012)

Injection Route and TLR9 Agonist Addition Significantly Impact Heroin Vaccine Efficacy
por: Bremer, Paul T., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_n4nkiesbfqp57o65pimk09rikq